PURPOSE: (11)C-labelled 1-[(S)-1-(2,3-dihydrobenzo[1,2]dioxin-2-yl)methyl]-4-(3-methoxy-methylpyridin-2-yl)-piperazine ((11)C-ORM-13070) is a novel PET tracer for imaging of α2C-adrenoceptors in the human brain. Brain α2C-adrenoceptors may be therapeutic targets in several neuropsychiatric disorders, including depression, schizophrenia and Alzheimer's disease. To validate the use of (11)C-ORM-13070 in humans, we investigated its radiometabolism, pharmacokinetics, whole-body distribution and radiation dose. METHODS: Radiometabolism was studied in a test-retest setting in six healthy men. After intravenous injection of (11)C-ORM-13070, blood samples were drawn over 60 min. Plasma samples were analysed by radio-HPLC for intact tracer and its radioactive metabolites. Metabolite-corrected plasma time-activity curves were used for calculation of pharmacokinetics. In a separate group of 12 healthy men, the whole-body distribution of (11)C-ORM-13070 and radiation exposure were investigated by dynamic PET/CT imaging without blood sampling. RESULTS: Two radioactive metabolites of (11)C-ORM-13070 were detected in human arterial plasma. The proportion of unchanged (11)C-ORM-13070 decreased from 81 ± 4 % of total radioactivity at 4 min after tracer injection to 23 ± 4 % at 60 min. At least one of the radioactive metabolites penetrated into red blood cells, while the parent tracer remained in plasma. The apparent elimination rate constant and corresponding half-life of unchanged (11)C-ORM-13070 in arterial plasma were 0.0117 ± 0.0056 min(-1) and 73.6 ± 35.8 min, respectively. The organs with the highest absorbed doses were the liver (12 μSv/MBq), gallbladder wall (12 μSv/MBq) and pancreas (9.1 μSv/MBq). The mean effective dose was 3.9 μSv/MBq, with a range of 3.6 - 4.2 μSv/MBq. CONCLUSION: (11)C-ORM-13070 was rapidly metabolized in human subjects after intravenous injection. The effective radiation dose of (11)C-ORM-13070 was in the same range as that of other (11)C-labelled brain receptor tracers. An injection of 500 MBq of (11)C-ORM-13070 would expose a subject to 2.0 mSv of radiation. This supports the use of (11)C-ORM-13070 in repeated PET scans, for example, in receptor occupancy trials with novel drug candidates.
PURPOSE: (11)C-labelled 1-[(S)-1-(2,3-dihydrobenzo[1,2]dioxin-2-yl)methyl]-4-(3-methoxy-methylpyridin-2-yl)-piperazine ((11)C-ORM-13070) is a novel PET tracer for imaging of α2C-adrenoceptors in the human brain. Brain α2C-adrenoceptors may be therapeutic targets in several neuropsychiatric disorders, including depression, schizophrenia and Alzheimer's disease. To validate the use of (11)C-ORM-13070 in humans, we investigated its radiometabolism, pharmacokinetics, whole-body distribution and radiation dose. METHODS: Radiometabolism was studied in a test-retest setting in six healthy men. After intravenous injection of (11)C-ORM-13070, blood samples were drawn over 60 min. Plasma samples were analysed by radio-HPLC for intact tracer and its radioactive metabolites. Metabolite-corrected plasma time-activity curves were used for calculation of pharmacokinetics. In a separate group of 12 healthy men, the whole-body distribution of (11)C-ORM-13070 and radiation exposure were investigated by dynamic PET/CT imaging without blood sampling. RESULTS: Two radioactive metabolites of (11)C-ORM-13070 were detected in human arterial plasma. The proportion of unchanged (11)C-ORM-13070 decreased from 81 ± 4 % of total radioactivity at 4 min after tracer injection to 23 ± 4 % at 60 min. At least one of the radioactive metabolites penetrated into red blood cells, while the parent tracer remained in plasma. The apparent elimination rate constant and corresponding half-life of unchanged (11)C-ORM-13070 in arterial plasma were 0.0117 ± 0.0056 min(-1) and 73.6 ± 35.8 min, respectively. The organs with the highest absorbed doses were the liver (12 μSv/MBq), gallbladder wall (12 μSv/MBq) and pancreas (9.1 μSv/MBq). The mean effective dose was 3.9 μSv/MBq, with a range of 3.6 - 4.2 μSv/MBq. CONCLUSION: (11)C-ORM-13070 was rapidly metabolized in human subjects after intravenous injection. The effective radiation dose of (11)C-ORM-13070 was in the same range as that of other (11)C-labelled brain receptor tracers. An injection of 500 MBq of (11)C-ORM-13070 would expose a subject to 2.0 mSv of radiation. This supports the use of (11)C-ORM-13070 in repeated PET scans, for example, in receptor occupancy trials with novel drug candidates.
Authors: M Scheinin; J W Lomasney; D M Hayden-Hixson; U B Schambra; M G Caron; R J Lefkowitz; R T Fremeau Journal: Brain Res Mol Brain Res Date: 1994-01
Authors: Veronica Fagerholm; Johanna Rokka; Leena Nyman; Jukka Sallinen; Jari Tiihonen; Erkki Tupala; Merja Haaparanta; Jarmo Hietala Journal: Synapse Date: 2008-07 Impact factor: 2.562
Authors: Jussi Lehto; Jere R Virta; Vesa Oikonen; Anne Roivainen; Pauliina Luoto; Eveliina Arponen; Semi Helin; Johanna Hietamäki; Aila Holopainen; Marita Kailajärvi; Juha M Peltonen; Juha Rouru; Jukka Sallinen; Kirsi Virtanen; Iina Volanen; Mika Scheinin; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2014-09-09 Impact factor: 9.236
Authors: Jussi Lehto; Jarkko Johansson; Lauri Vuorilehto; Pauliina Luoto; Eveliina Arponen; Harry Scheinin; Juha Rouru; Mika Scheinin Journal: Psychopharmacology (Berl) Date: 2015-04-29 Impact factor: 4.530
Authors: Sjoerd J Finnema; Zoë A Hughes; Merja Haaparanta-Solin; Vladimir Stepanov; Ryuji Nakao; Katarina Varnäs; Andrea Varrone; Eveliina Arponen; Päivi Marjamäki; Katariina Pohjanoksa; Lauri Vuorilehto; Phebian A Babalola; Olof Solin; Sarah Grimwood; Jukka Sallinen; Lars Farde; Mika Scheinin; Christer Halldin Journal: Int J Neuropsychopharmacol Date: 2014-12-13 Impact factor: 5.176
Authors: Sjoerd J Finnema; Mika Scheinin; Mohammed Shahid; Jussi Lehto; Edilio Borroni; Benny Bang-Andersen; Jukka Sallinen; Erik Wong; Lars Farde; Christer Halldin; Sarah Grimwood Journal: Psychopharmacology (Berl) Date: 2015-04-30 Impact factor: 4.530
Authors: Juha O Rinne; Keith Wesnes; Jeffrey L Cummings; Pasi Hakulinen; Merja Hallikainen; Jutta Hänninen; Michael Murphy; Henry Riordan; Mika Scheinin; Hilkka Soininen; Juha Rouru Journal: Alzheimers Dement (N Y) Date: 2016-12-08